Literature DB >> 14527081

Death receptor activation-induced hepatocyte apoptosis and liver injury.

Xiao-Ming Yin1, Wen-Xing Ding.   

Abstract

The TNFalpha receptor super-family consists of several members sharing a sequence homology in a unique function domain, the death domain, which is located in the intracellular portion of the receptor. These so-called death receptors, including Fas, TNF-R1 and TRAIL-R1/TRAIL-R2, are expressed on hepatocytes. When stimulated by their ligands, FasL, TNFalpha or TRAIL, respectively, the death receptors can activate multiple death domain-initiated apoptosis programs, including both extrinsic and intrinsic pathways. A cascade of caspases is activated, which cleave proteins important for the cell structure and function. Activation of the intrinsic pathway also leads to mitochondrial release of several apoptotic proteins and mitochondrial dysfunction, which kill the cell through both caspase-dependent and caspase-independent mechanisms. Death receptor-induced hepatocyte apoptosis contributes to the development of a number of liver diseases, including viral hepatitis, inflammatory hepatitis, Wilson's disease, alcoholic liver disease, endotoxiemia-induced liver failure and ischemia/reperfusion-induced liver damage. This article comprehensively reviews the mechanisms of induction and regulation of death receptor-initiated apoptosis in hepatocytes, examines how these molecular events affect our understanding of the pathogenesis of these diseases and further discusses the potential therapeutic application of the knowledge. We hope we can provide a cohesive and integrated perspective on the many aspects of these complicated processes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14527081     DOI: 10.2174/1566524033479555

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  44 in total

1.  Vitamin D ameliorates hepatic ischemic/reperfusion injury in rats.

Authors:  Ansam Aly Seif; Doaa Mohamed Abdelwahed
Journal:  J Physiol Biochem       Date:  2014-04-22       Impact factor: 4.158

2.  Exploring Crimean-Congo Hemorrhagic Fever Virus-Induced Hepatic Injury Using Antibody-Mediated Type I Interferon Blockade in Mice.

Authors:  Michael E Lindquist; Xiankun Zeng; Louis A Altamura; Sharon P Daye; Korey L Delp; Candace Blancett; Kayla M Coffin; Jeffrey W Koehler; Susan Coyne; Charles J Shoemaker; Aura R Garrison; Joseph W Golden
Journal:  J Virol       Date:  2018-10-12       Impact factor: 5.103

Review 3.  Chronic hepatitis B in hepatocarcinogenesis.

Authors:  N H Park; I H Song; Y-H Chung
Journal:  Postgrad Med J       Date:  2006-08       Impact factor: 2.401

4.  Generation of aberrant forms of DFF40 concurrent with caspase-3 activation during acute and chronic liver injury in rats.

Authors:  Yiwen Xiang; Erik A Johnson; Chun Zhang; Guangling Huang; Ronald L Hayes; Kevin K W Wang; Stanislav I Svetlov
Journal:  Biochem Biophys Res Commun       Date:  2006-09-22       Impact factor: 3.575

5.  Molecular Pathogenesis of Hepatitis-B-virus-associated Hepatocellular Carcinoma.

Authors:  Neung Hwa Park; Il Han Song; Young-Hwa Chung
Journal:  Gut Liver       Date:  2007-12-31       Impact factor: 4.519

6.  Responses of nontransformed human hepatocytes to conditional expression of full-length hepatitis C virus open reading frame.

Authors:  Weiliang Tang; Catherine A Lázaro; Jean S Campbell; W Tony Parks; Michael G Katze; Nelson Fausto
Journal:  Am J Pathol       Date:  2007-11-08       Impact factor: 4.307

7.  Fas-disabling small exocyclic peptide mimetics limit apoptosis by an unexpected mechanism.

Authors:  Akihiro Hasegawa; Xin Cheng; Kiichi Kajino; Alan Berezov; Kaoru Murata; Toshinori Nakayama; Hideo Yagita; Ramachandran Murali; Mark I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-14       Impact factor: 11.205

Review 8.  A Mechanistic Review of Cell Death in Alcohol-Induced Liver Injury.

Authors:  Shaogui Wang; Pal Pacher; Robert C De Lisle; Heqing Huang; Wen-Xing Ding
Journal:  Alcohol Clin Exp Res       Date:  2016-04-30       Impact factor: 3.455

9.  Mutations to bid cleavage sites protect hepatocytes from apoptosis after ischemia/reperfusion injury.

Authors:  Erica Riddle-Taylor; Kazuhito Nagasaki; Joseph Lopez; Carlos O Esquivel; Olivia M Martinez; Sheri M Krams
Journal:  Transplantation       Date:  2007-09-27       Impact factor: 4.939

10.  Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer.

Authors:  T Trarbach; M Moehler; V Heinemann; C-H Köhne; M Przyborek; C Schulz; V Sneller; G Gallant; S Kanzler
Journal:  Br J Cancer       Date:  2010-01-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.